Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

Objective This literature review assessed the burden of treatment-resistant depression in the
United States by compiling published data about the clinical, societal, and economic …

Objective: Estimates of prevalence and burden of treatment-resistant depression (TRD) vary
widely in the literature. This study evaluated the prevalence and burden of TRD and the …

Background: Treatment utilization/costs and work performance for persons with major
depressive disorder (MDD) by severity of illness is not well documented. Methods: Using …

BACKGROUND: Major depressive disorder (MDD) is a leading cause of disability, morbidity,
and mortality worldwide. The lifetime prevalence in the United States is estimated at 17 …

Abstract Treatment-resistant depression (TRD) presents major challenges for both patients
and clinicians. There is no universally accepted definition of TRD, but results from the US …

Objective: Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine
combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression …

Objective: To develop a claims-based scale for treatment-resistant depression (TRD) and
estimate the associated direct cost burden. Study Design: Retrospective, observational study …

Context Treatment Resistant Depression (TRD) is a significant and burdensome health
concern. Objective To characterize, compare and understand the difference between TRD …

Depression imposes significant costs on sufferers, their families and care-givers, employers
and insurance payers. This article summarises medical and health economics literature …